Please assess the completion status of the following clinical trial:

Trial Title: Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 70 years old~* Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB\> or = 4 cm to IV, according to FIGO classification) histologically proven~* Measurable lesions,clinically and by MRI assessed~* PS-WHO \< or = 2 ou Karnofsky Index \>70 per cent~* Life expectancy \> 3 months~* Hematologic function: leukocytes \< or = 3 G/l, polynuclear neutrophil leukocytes \> or = 1.5 G/l, platelets \> or = 100 G/l, hemoglobin \> or = 10 g/dl~* Hepatic function: ASAT and ALAT \< 2.5 ULN~* Renal function: creatininemia \< 1.5 ULN, clearance \> 60 ml/min~* No prior chemotherapy or radiotherapy~* Contraception~* Written informed consent signed~Exclusion Criteria:~* Stage IB \< 4 cm or IVB~* Other histology than epidermoid or adenocarcinoma~* Distant metastases, including sus-clavicular adenopathy~* Contraindication to MRI~* Pregnant or lactating woman~* Auto-immune disease~* Peripheric neuropathy, autograft or homograft, psychiatric disease~* Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma in situ)~* Active infection~* Other clinical trial with an experimental drug~* Known positive serology (HIV, HbC, HbS)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- patient with cervix cancer (Type: EXPERIMENTAL): will receive gemcitabine + cisplatin + radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).